obesity drug news today glp-1 2025 oct 27 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes Beyond GLP-1: the next wave

MEDI0382, a GLP-1 and Glucagon Receptor Dual Agonist, in Obese or Overweight Patients With Type 2 Diabetes: A Randomised, Controlled, Double-Blind, Ascending Dose and Phase 2a Study

L-Glutamine 2

If this happens, you may need additional treatment or surgery

SonJKimMParkYBaekKYooSSongKet alAssociation of serum bone morphogenetic protein 4 levels with obesity and metabolic syndrome in non-diabetic individuals

Let's start with understanding what cagrilintide is and why it's so effective for weight loss

Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation